Success Stories: University-Petitioned EB-1B Approved for Assistant Research Professor in Louisiana in the Field of Viral Immunology
Client’s Testimonial:
“Thank you for your help.”
On March 2nd, 2017, we received another EB-1B (Outstanding Professors and Researchers) approval for an Assistant Research Professor in the Field of Viral Immunology (Approval Notice).
General Field: Viral Vaccines and Immunology
Position at the Time of Case Filing: Assistant Research Professor
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Louisiana
Approval Notice Date: March 2nd, 2017
Processing Time: 13 days (Premium Processing Requested)
Case Summary:
Just 13 days after North America Immigration Law Group (NAILG) filed an EB-1B (Outstanding Professors and Researchers) petition on behalf of a client from India, we received an approval notice from the USCIS. Our client’s position as an assistant research professor has allowed him to focus his research on developing vaccines for viral infections, particularly for HIV/AIDS, with applications towards developing new vaccines, lowering death rates, and reducing medical costs.
Before we took him on as a client, we examined his credentials to confirm that we could build a strong EB-1B case for him. Furthermore, as EB-1B is an employer-sponsored I-140 category, we made sure that our client had his employer’s full support before proceeding. After we determined him to be a suitable candidate for EB1B, we proceeded to detail his various research achievements which included the following:
- His consistent publication record of 9 peer-reviewed scientific articles, one patent, and two editor’s notes: the relevance of these publications can be judged from the 37 citations that they have amassed.
- We also proved his active participation in the field of viral immunology by highlighting the 30 peer reviews that he has conducted over the years.
- We included several recommendation letters signed by other experts in the field. They supported the approval of our client’s EB1B petition by noting the importance of his studies on the development of one of the most effective HIV vaccines—currently under clinical trials in the US. According to one of our client’s recommenders: “The health of innumerable patients hinges on his favorable research outcomes arid as I have seen that he has completed highly successful studies in the past he is capable of achieving this in the future too.”
In the end, NAILG provided sufficient evidence proving that our client’s research addresses some of the United States’ most pressing issues in understanding matters concerning public health. We congratulate our client for securing EB-1B petition approval, and we thank him for working with us.